GLP-1 / metabolic
Cagrilintide
Used in research on satiety, appetite and body weight (amylin analogue; often with GLP-1).
What it is used for
- Appetite control (amylin analogue)
- Body-weight reduction in research
- Combinations with incretin agonists (e.g. with retatrutide)
- Food-intake regulation / satiety
Disclaimer — Research Use Only
Materials listed on this website are supplied for laboratory research only (Research Use Only). They are not intended for human consumption.
Quick Facts
- Category
- GLP-1 / metabolic
- Research status
- Early clinical research
- Strength (illustration)
- 10 mg
- Price-list variants
- 10mg · 5mg
- Also known as
- —
Overview
Cagrilintide is a long-acting amylin analogue evaluated in appetite and body-weight research, often in combinations with GLP-1 agonists.
What it is used for
Community and research context — not a medical indication or treatment advice.
- Appetite control (amylin analogue)
- Body-weight reduction in research
- Combinations with incretin agonists (e.g. with retatrutide)
- Food-intake regulation / satiety
Cagrilintide is discussed mainly as an appetite-control tool — an amylin analogue (a satiety hormone). Trials appear both alone and combined with incretin peptides (hence retatrutide + cagrilintide research bundles). It is not a “burner” or a substitute for a calorie deficit; the narrative is satiety and lower intake.
For people exploring metabolic combinations and wanting to understand the “second mechanism” beside GLP-1.
How it works
Amylin acts in satiety centres and influences gastric emptying rate. Cagrilintide as a long-acting mimetic aims to use those pathways. In combinations with GLP-1/GIP, trials often target stronger appetite control than a single mechanism alone.
Amylin contributes to satiety and gastric-emptying regulation. Amylin analogues in research aim to amplify these signals within controlled protocols.
How it is used (research context)
From protocols and documentation — not a dosing guide.
Research protocols usually use subcutaneous dosing on the study schedule. Reconstitution and dosing are not a “gym guide” topic — they belong to a protocol or clinician. In combinations, GI adverse effects can add up.
Key takeaways
- Think: satiety / amylin — not tendon repair
- Often mentioned alongside retatrutide / sema / tirz
- Less mainstream media coverage than semaglutide — be careful with claims
- MarcinLabs education = context, not a protocol
Who this content is for: For people exploring metabolic combinations and wanting to understand the “second mechanism” beside GLP-1.
Current research
Early clinical research
Data come mainly from early-to-mid clinical phases; registration status may be limited or unavailable in many countries.
Contexts from literature — not therapeutic indications.
- Appetite control
- Body weight
- Combinations with GLP-1 / dual agonists
- GI profile
Potential side effects
- Nausea and gastrointestinal symptoms
- Limited long-term safety data
- Interaction risk when combined with other metabolic peptides
Frequently asked questions
Why is cagrilintide listed with retatrutide on the price list?
Related scientific papers
Cagrilintide–semaglutide combination research (overview)
2021–2024
Search PubMed for current reviews under cagrilintide.
PubMed / source →Related YouTube videos
YouTube HubNo matching videos — see the YouTube Hub.
Related MarcinLabs articles
ResearchNo direct notes — see the Research Hub.
Related peptides
Retatrutide
Used in research on substantial body-composition research, appetite and metabolism (GIP/GLP-1/glucagon triple agonist).
Tirzepatide
Used for weight reduction, appetite and glycaemic control (dual GIP/GLP-1 agonist).
Semaglutide
Used in research and clinic for body weight, appetite and type 2 diabetes (GLP-1 agonist).
In the research library
Retatrutide 5mg + Cagrilintide 5mg · Cagrilintide